Home
About
FAQ
History (22)
6,6-Diphenyl-6,7-dihydro-5H-1,3,4,8-tetrathia-6-stannazulene-2-thione and 6,6'-spirobi[6,7-dihydro-5H-1,3,4,8-tetrathia-6-stannazulene]-2,2'-dithione.
Receptors, Purinergic P1
Resection of the scaphoid distal pole for symptomatic scaphoid nonunion after failed previous surgical treatment.
Single Season Changes in Resting State Network Power and the Connectivity between Regions: Distinguish Head Impact Exposure Level in High School and Youth Football Players.
What's new in the topical treatment of allergic skin diseases.
See All 22 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
What's new in the topical treatment of allergic skin diseases.
Aslam I, Sandoval LF, Feldman SR. What's new in the topical treatment of allergic skin diseases. Curr Opin Allergy Clin Immunol. 2014 Oct; 14(5):436-50.
View in:
PubMed
subject areas
Administration, Topical
Adrenal Cortex Hormones
Anti-Inflammatory Agents
Dermatitis, Allergic Contact
Dermatitis, Atopic
Evidence-Based Medicine
Humans
Lipoxins
Randomized Controlled Trials as Topic
Skin
Urocanic Acid
authors with profiles
Steven R. Feldman MD, PhD